Nonalcoholic fatty liver disease (NAFLD) is composed of nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH) and NASH related cirrhosis and these are defined by histological findings. These diseases have absolutely typical and different clinical findings and natural courses respectively. NAFL generally has benign process however; NASH and NASH related cirrhosis have an increased risk for liver-related morbidity and mortality. So, the accurate diagnosis and differentiation of steatohepatitis or advanced fibrosis are essential in the management of patient and the prediction of prognosis. The gold-standard of diagnosis of NAFLD is liver biopsy however; it has some limitations in clinical practice. So many studies have been done to find out noninvasive diagnostic methods. These methods can be divided into 2 groups: those that predict the presence of NASH and that predict the presence of advanced fibrosis. This paper provides an overview of various noninvasive methods for detecting NAFLD and their clinical meanings in clinical practice. ( 
-406 -정도 높은 것으로 알려져 있다 [13] . 따라서 Table 2) . NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; ALT, alanine aminotransferase; AUROC, area under receiver operating characteristic; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; TIMP-1, tissue inhibitor of metalloproteinases; NASH, non-alcoholic steatohepatitis; GGT, gamma-glutamyltranspeptidase; IFG, increased fasting glucose; AST, aspartate aminotransferase. The most significant prognostic factor is the fibrosis severity, hence is the first one to be screened. If NFS suggests advanced fibrosis, it is essential to exclude cirrhosis, which needs special management, and a liver biopsy is recommended. If the NFS suggests low probability for advanced fibrosis, this can be excluded for fibrosis. However, the exclusion of NASH is still important and if CK18 is available we can try it for the next steps. If it suggests NASH, it should be confirmed by liver biopsy, since it will be a false positive in 14% of the patients. In the patients unclassified for NFS, FibroScan® can be useful, with the need to confirm cirrhosis with liver biopsy if it suggests advanced fibrosis (modified with Reference 13). 
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